Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national
90
×
national blog main
life sciences
national top stories
biotech
boston blog main
boston top stories
san francisco blog main
san francisco top stories
new york blog main
san diego blog main
san diego top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
texas top stories
seattle blog main
texas blog main
wisconsin blog main
detroit blog main
seattle top stories
wisconsin top stories
boulder/denver blog main
detroit top stories
boulder/denver top stories
indiana blog main
indiana top stories
fda
clinical trials
cancer
novartis
pfizer
bristol-myers squibb
merck
startups
gene therapy
eli lilly
amgen
cancer immunotherapy
deals
What
roundup
bio
drug
new
medical
cancer
life
medicine
fda
week
sciences
drugs
companies
health
ipo
science
xcelerating
biotech
breakthroughs
digital
future
gene
learn
medicines
accelerating
annual
attend
biopharma's
biopharma’s
boston
conference
crispr
join
news
patients
plan
prices
registering
team
tech
Language
unset
unknown
Current search:
national
×
@xconomy.com
4 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
4 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
4 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Explore San Diego’s Precision Medicine and Genomics Sector in Xconomy’s New Podcast and Special Report
@xconomy.com
4 years ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
5 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
5 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
5 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
5 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
First
Prev
Page 1
(current)
Next
Last